Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production

American Journal of Transplantation

Volumn 9, Issue 1, 2009, Pages 201-209

  Perry, D K ^a   Burns, J M ^a   Pollinger, H S ^a   Amiot, B P ^b   Gloor, J M ^a   Gores, G J ^a   Stegall, M D ^a  

^a Mayo Clinic   (United States)

^b Brami Biomedical Inc   (United States)

Author keywords

Antibody production; Plasma cell; Proteasome inhibition

Indexed keywords

ALLOANTIBODY; BORTEZOMIB; CASPASE 3; CASPASE 7; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; PROTEASOME; RITUXIMAB; TETANUS ANTIBODY; THYMOCYTE ANTIBODY;

ABSENCE OF SIDE EFFECTS; ACUTE GRAFT REJECTION; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOGLOBULIN PRODUCTION; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; PERIPHERAL NEUROPATHY; PLASMA CELL; PLASMAPHERESIS; PRIORITY JOURNAL;

ANTIBODY SPECIFICITY; APOPTOSIS; BORONIC ACIDS; CYSTEINE PROTEINASE INHIBITORS; GRAFT REJECTION; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; PLASMA CELLS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 58049200722     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02461.x     Document Type: Article

References (33)

1. Fairfax KA, Kallies A, Nutt SL, Tarlinton DM. Plasma cell development: From B-cell subsets to long-term survival niches. Seminars Immunol 2008 20 : 49 58.
2. Heeringa P, Tervaert JW. Pathophysiology of ANCA-associated vasculitides: Are ANCA really pathogenic? Kidney Int 2004 65 : 1564 1567.
3. Barratt J, Feehally J, Smith AC. Pathogenesis of IgA nephropathy. Semin Nephrol 2004 24 : 197 217.
4. Schweitzer E, Wilson JS, Fernandez-Vina M et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 2000 70 : 1531 1536.
5. Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000 70 : 887 895.
6. Jordan SC. Management of the highly HLA-sensitized patient. A novel role for intravenous gammaglobulin. Am J Transplant 2002 2 : 691 692.
7. Glotz D, Antoine C, Julia P et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulin. Am J Transplant 2002 2 : 758 760.
8. Jordan SC, Tyan D, Stablein D et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 2004 15 : 3256 3262.
9. Stegall MD, Gloor JM, Winters J, Moore SB. A comparison of plasmapheresis vs. high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006 6 : 346 351.
10. Gloor JM, Sethi S, Stegall MD et al. Transplant glomerulopathy: Subclinical incidence and association with alloantibody. Am J Transplant 2007 7 : 2124 2132.
11. Cosio FG, Gloor JM, Sethi S, Stegall MD. Transplant glomerulopathy. Am J Transplant 2008 8 : 492 496.
12. Perry D, Pollinger H, Stegall MD et al. Two novel assays of alloantibody secreting cells demonstrating resistance to desensitization with IVIG and rATG. Am J Transplant 2008 8 : 133 143.
13. Viera CA, Agarwal A, Book BK et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: Safety, pharmacodynamics and pharmacokinetics. Transplantation 2004 77 : 542 548.
14. Genberg H, Hansson A, Wernerson A, Wennberg L, Tyden G. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 2006 6 : 2418 2428.
15. Zand MS, Thuong V, Huggins J et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005 79 : 1507 1515.
16. Jacson G, Einsele H, Moreau P, Miguel JS. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer Treat Rev 2005 31 : 591 602.
17. Jagannath S, Barlogie B, Berenson JR et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 2005 103 : 1195 1200.
18. Berenson JR, Jagannath S, Barlogie B et al. Safety and prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 2005 104 : 2141 2148.
19. Nencioni A, Grunebach F, Patrone F, Ballestro A, Brossert P. Proteasome inhibitors: Antitumor effects and beyond. Leukemia 2007 21 : 30 36.
20. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibitions measurements: Clinical application. Clin Chem 2000 46 : 673 683.
21. Ramos EJ, Pollinger HS, Stegall MD, Gloor JM, Dogan A, Grande JP. The effect of desensitization on human splenic B cell populations in vivo. Am J Transplant 2007 7 : 402 407.
22. Chambers SA, Isenberg D. Anti-B cell therapy (Rituximab) in the treatment of autoimmune diseases. Lupus 2005 14 : 210 214.
23. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004 350 : 2572 2581.
24. Ruggenenti P, Chiurchiu C, Abbate M et al. Rituximab for idiopathic membranous nephropathy: Who can benefit? Clin J Am Soc Nephrol 2006 1 : 738 748.
25. Toyada M, Pao, Petrosia A, Jordan SC. Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells. Am J Transplant 2003 3 : 156 166.
26. Neubert K, Meister S, Moser K et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008 14 : 748 755.
27. Cascio P, Oliva L, Cerruti F et al. Dampening Ab responses using proteasome inhibitors following in vivo B cell activation. Eur J Immunol 2008 38 : 658 667.
28. Ravetch JV, Nussenzweig M. Killing some to make way for others. Nat Immunol 2007 8 : 337 339.
29. Moser K, Tokoyoda Km Radbruch A, MacLennan I, Manz RA. Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol 2006 18 : 265 270.
30. Schubert U, Anton LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR. Rapid degredation of a large fraction of newly synthesized proteins by proteasomes. Nature 2000 404 : 770 774.
31. Yewdell JW, Anton LC, Bennink JR. Defective ribosomal products (DRiPs): A major source of antigenic peptides for MHC class I molecules? J Immunol 1996 157 : 1823 1826.
32. Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005 23 : 4776 4789.
33. Cenci S, Mezghrani A, Cascio P et al. Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J 2006 25 : 1104 1113.